TSX · Biotechnology · CAD

Aptose Biosciences Inc. (APS.TO) Stock Analysis

Aptose Biosciences Inc. (APS.TO) is a Biotechnology stock listed on TSX and quoted in Canadian Dollar.

APS.TO

CA$2.40

+CA$0.12 (+5.26%)

Last trade July 3, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare APS.TO with… →

APS.TO Key Statistics

As of Jul 3, 2026

Trading

Open: CA$2.40
Previous Close: CA$2.28
52-Week Range: 1.02–2.59
Volume: 2.94K

Valuation

Market Cap: CA$5.82M
P/E Ratio: unprofitable
EPS (ttm): −14.37

Financials (FY)

Revenue (FY): CA$0.00
Net Income (FY): −CA$25.47M
Profit margin: 0.00%
1-Year Return: +101.68%

Dividend and dates

Avg Volume: 3.46K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

APS.TO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

Year	Return
2026 (partial year)	+13.21%
2025 (partial year)	−58.75%

As of July 3, 2026.

APS.TO Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	CA$0.00	−CA$25.47M	—
2024	CA$0.00	−CA$25.43M	—
2023	CA$0.00	−CA$51.21M	—
2022	CA$0.00	−CA$41.82M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	CA$0.00	—	−CA$24.72M	−CA$25.47M	—
2024	CA$0.00	—	−CA$26.26M	−CA$25.43M	—
2023	CA$0.00	—	−CA$52.36M	−CA$51.21M	—
2022	CA$0.00	—	−CA$42.60M	−CA$41.82M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

APS.TO Valuation vs Biotechnology Median

Median of 656 stocks

Metric	APS.TO	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values Aptose Biosciences Inc. (APS.TO) at CA$5.82M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 14 employees.

Over the past 52 weeks the price has ranged from CA$1.02 to CA$2.59. The most recent close on file for APS.TO is CA$2.40, dated July 3, 2026. That is +CA$0.12 (+5.26%) against the previous close. The latest close sits 135.29% above that 52-week low.

Financial Health

In fiscal 2025, Aptose Biosciences Inc. reported revenue of CA$0.00. The same year closed with a net loss of CA$25.47M. Profit margin runs at 0%. Trailing earnings per share are −14.37.

Across the 4 fiscal years on file, revenue moves from CA$0.00 in 2022 to CA$0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Daily returns over the trailing 1 year annualize to a volatility of 82.51%. The trailing one-year price return is +101.68%.

Growth & Income

The record shows no dividend for APS.TO.

So far in 2026 the price is +13.21%.

Peer Comparison

Aptose Biosciences Inc. (APS.TO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Aptose Biosciences Inc.	APS.TO	CA$5.82M	—
Vertex Pharmaceuticals Incorporated	VRTX	CA$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	CA$85.22B	20.5
argenx SE	ARGX	CA$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Aptose Biosciences Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of July 3, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Aptose Biosciences Inc.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes. It has license agreements with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Visit website →